HemoCue
Private Company
Funding information not available
Overview
HemoCue is a long-established, global leader in point-of-care (POC) diagnostic systems, with a core focus on hemoglobin testing for anemia and glucose monitoring for diabetes. The company serves a wide range of clinical settings including primary care, hospitals, public health programs, and blood banks, emphasizing accuracy, portability, and workflow efficiency. With over 430 employees and a presence in numerous countries, HemoCue leverages decades of engineering expertise to support healthcare workers worldwide. Its recent brand revitalization and strategic partnerships, such as with Novo Nordisk, indicate an active strategy to expand its market influence and clinical impact.
Technology Platform
Proprietary point-of-care diagnostic systems based on microcuvette technology and photometric analysis for hematology (e.g., hemoglobin) and diabetes (glucose) testing. The platform emphasizes closed-system, single-use cuvettes for sample handling and portable, easy-to-use analyzers delivering lab-accurate results.
Opportunities
Risk Factors
Competitive Landscape
HemoCue competes in the crowded point-of-care diagnostics market against global giants like Abbott (i-STAT, Afinion), Roche (Cobas, Accu-Chek), Siemens Healthineers (Epoc, Rapidpoint), and Danaher (Radiometer, Beckman Coulter). Its differentiation is built on a long-standing reputation for accuracy and robustness in specific niches like hemoglobin testing, particularly in blood banks and field settings, where its portable, simple systems have strong loyalty.